Previous 10 | Next 10 |
2024-03-19 13:15:03 ET Summary AstraZeneca is acquiring Fusion Pharmaceuticals for up to $2.4 billion to expand its presence in the radiopharmaceuticals market. The acquisition includes Fusion's late-stage radiopharmaceutical candidate, FPI-2265, a potential treatment of metastati...
2024-03-19 12:31:34 ET More on Actinium Pharmaceuticals Actinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upgrade) Actinium shares surge on promising data for AML radiotherapy candidate Actinium, Fusion stocks rally on $4.1B RayzeBio takeover deal ...
2024-03-19 10:16:19 ET Summary Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows. Deal volume should remain strong in 2024 as large pharma concerns have large cash balances, face key patent expirations ...
Includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage ...
2024-03-19 05:43:23 ET More on related stocks: StoneCo Q4 Earnings: I Made A Mistake (Rating Downgrade) StoneCo Ltd. (STNE) Q4 2023 Earnings Call Transcript National CineMedia, Inc. (NCMI) Q4 2023 Earnings Call Transcript AstraZeneca will buy Fusion Pharmaceu...
2024-03-19 04:10:27 ET More on AstraZeneca & Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook AstraZeneca to cap costs of inhalers at $35 per month AstraZeneca to expand ...
2024-03-18 15:36:31 ET More on Puma Biotechnology Puma Biotechnology, Inc. 2023 Q4 - Results - Earnings Call Presentation Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Puma Biotechnology Historical ear...
2024-03-18 12:17:28 ET More on AstraZeneca 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca FY23 Earnings Review: It's OK To Buy Dip On Q4 Bottom Line Miss AstraZeneca to expand rare disease pipel...
2024-03-18 10:00:07 ET Summary Novo Nordisk's Wegovy represents a significant advancement in obesity treatment, demonstrating a more profound weight-loss effect compared to its predecessor, Saxenda. Eli Lilly's entry with Zepbound, targeting both GLP-1 and GIP, signifies a competi...
2024-03-18 07:04:31 ET Summary Today, we look at Mineralys Therapeutics, a clinical-stage biotechnology company focused on developing treatments for diseases driven by elevated aldosterone levels. The company's sole asset, lorundrostat, is an aldosterone synthase inhibitor that ha...
News, Short Squeeze, Breakout and More Instantly...
2024-07-20 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...